The Phase III trial of fruquintinib in advanced non-small cell lung cancer patients did not meet the primary endpoint of increasing overall survival, despite improvements in progression-free survival. The Phase III FALUCA trial was conducted on patients in China and failed the two lines of systemic chemotherapy.
Fruquintinib provided a statistically significant improvement in all secondary endpoints compared to placebo, including objective response rate, disease control rate, progression-free survival and the duration of response. The safety profile of the trial was in line with expectations.
Simon To, Chairman of Chi-Med commented: “We remain confident that the high selectivity and lower off-target toxicities of fruquintinib are major points of differentiation. The recent first approval of fruquintinib monotherapy for advanced colorectal cancer, the imminent launch in China, and the commencement of several combination collaborations with immunotherapies both in China and in the U.S., reinforces our belief in fruquintinib.”